FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3185280489> ?p ?o ?g. }

• W3185280489 endingPage "145" @default.
• W3185280489 startingPage "138" @default.
• W3185280489 abstract "Degarelix is associated with high rates of injection site reaction. The US Food and Drug Administration approved relugolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of advanced prostate cancer patients.This systematic review and network meta-analysis aimed to compare the efficacy and safety of relugolix versus degarelix.A systematic search was performed using major web databases for studies published before January 30, 2021, according to the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) extension statement for a network meta-analysis. Studies that compared the efficacy (12-mo castration rate with testosterone ≤50 ng/dl) and safety (adverse events [AEs]) of relugolix or degarelix and of the control group (GnRH agonists) were included. We used the Bayesian approach in the network meta-analysis.Four studies (n = 2059) met our eligibility criteria. The main efficacy analysis was conducted for two different treatments (relugolix and all doses of degarelix vs GnRH agonists); relugolix (risk ratio [RR] 1.09, 95% credible interval [CrI]: 0.95-1.23) and degarelix (RR 0.98, 95% CrI: 0.91-1.06) were not associated with different 12-mo castration rates. In the subgroup analysis, degarelix 480 mg was significantly associated with a lower castration rate (RR 0.46, 95% CrI: 0.07-0.92). In all efficacy ranking analyses, relugolix achieved the best rank. The safety analyses showed that relugolix (RR 0.99, 95% CrI: 0.6-1.6 and RR 0.72, 95% CrI: 0.4-1.3, respectively) and degarelix (RR 1.1, 95% CrI: 0.75-1.35 and RR 1.05, 95% CrI: 0.42-2.6, respectively) were not associated with either all AE or serious AE rates. In the ranking analyses, degarelix achieved the worst rank of all AEs and the best rank of serious AEs. Relugolix (RR 0.44, 95% CrI: 0.16-1.2) and degarelix (RR 0.74, 95% CrI: 0.37-1.52) were not associated with different cardiovascular event (CVE) rates; both were associated with lower CVE rates than GnRH agonists in the ranking analyses.We found that the efficacy and safety of relugolix are comparable with those of degarelix, albeit with no injection site reaction. Such data should be interpreted with caution until large-scale direct comparison studies with a longer follow-up are available.We found that relugolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, has comparable efficacy and safety with degarelix, a parenteral GnRH antagonist, for the treatment of advanced prostate cancer patients." @default.
• W3185280489 created "2021-08-02" @default.
• W3185280489 creator A5001883861 @default.
• W3185280489 creator A5002599364 @default.
• W3185280489 creator A5014044970 @default.
• W3185280489 creator A5030402975 @default.
• W3185280489 creator A5032679795 @default.
• W3185280489 creator A5038102022 @default.
• W3185280489 creator A5038866794 @default.
• W3185280489 creator A5044228660 @default.
• W3185280489 creator A5046703631 @default.
• W3185280489 creator A5058063575 @default.
• W3185280489 creator A5074919720 @default.
• W3185280489 creator A5079401169 @default.
• W3185280489 creator A5086463674 @default.
• W3185280489 creator A5087973088 @default.
• W3185280489 date "2022-04-01" @default.
• W3185280489 modified "2023-09-30" @default.
• W3185280489 title "The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials" @default.
• W3185280489 cites W1617328014 @default.
• W3185280489 cites W2016927496 @default.
• W3185280489 cites W2049161486 @default.
• W3185280489 cites W2054632912 @default.
• W3185280489 cites W2070496808 @default.
• W3185280489 cites W2120974167 @default.
• W3185280489 cites W2156659229 @default.
• W3185280489 cites W2161817962 @default.
• W3185280489 cites W2795707114 @default.
• W3185280489 cites W2976578307 @default.
• W3185280489 cites W3011615314 @default.
• W3185280489 cites W3019350884 @default.
• W3185280489 cites W3032046986 @default.
• W3185280489 cites W3037221203 @default.
• W3185280489 cites W3082139355 @default.
• W3185280489 cites W4210406669 @default.
• W3185280489 doi "https://doi.org/10.1016/j.euo.2021.07.002" @default.
• W3185280489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34301529" @default.
• W3185280489 hasPublicationYear "2022" @default.
• W3185280489 type Work @default.
• W3185280489 sameAs 3185280489 @default.
• W3185280489 citedByCount "5" @default.
• W3185280489 countsByYear W31852804892021 @default.
• W3185280489 countsByYear W31852804892022 @default.
• W3185280489 countsByYear W31852804892023 @default.
• W3185280489 crossrefType "journal-article" @default.
• W3185280489 hasAuthorship W3185280489A5001883861 @default.
• W3185280489 hasAuthorship W3185280489A5002599364 @default.
• W3185280489 hasAuthorship W3185280489A5014044970 @default.
• W3185280489 hasAuthorship W3185280489A5030402975 @default.
• W3185280489 hasAuthorship W3185280489A5032679795 @default.
• W3185280489 hasAuthorship W3185280489A5038102022 @default.
• W3185280489 hasAuthorship W3185280489A5038866794 @default.
• W3185280489 hasAuthorship W3185280489A5044228660 @default.
• W3185280489 hasAuthorship W3185280489A5046703631 @default.
• W3185280489 hasAuthorship W3185280489A5058063575 @default.
• W3185280489 hasAuthorship W3185280489A5074919720 @default.
• W3185280489 hasAuthorship W3185280489A5079401169 @default.
• W3185280489 hasAuthorship W3185280489A5086463674 @default.
• W3185280489 hasAuthorship W3185280489A5087973088 @default.
• W3185280489 hasBestOaLocation W31852804891 @default.
• W3185280489 hasConcept C121608353 @default.
• W3185280489 hasConcept C126322002 @default.
• W3185280489 hasConcept C126894567 @default.
• W3185280489 hasConcept C143998085 @default.
• W3185280489 hasConcept C168563851 @default.
• W3185280489 hasConcept C17744445 @default.
• W3185280489 hasConcept C187960798 @default.
• W3185280489 hasConcept C189708586 @default.
• W3185280489 hasConcept C197934379 @default.
• W3185280489 hasConcept C199539241 @default.
• W3185280489 hasConcept C2779473830 @default.
• W3185280489 hasConcept C2780192828 @default.
• W3185280489 hasConcept C29456083 @default.
• W3185280489 hasConcept C44249647 @default.
• W3185280489 hasConcept C71924100 @default.
• W3185280489 hasConcept C82789193 @default.
• W3185280489 hasConcept C95190672 @default.
• W3185280489 hasConceptScore W3185280489C121608353 @default.
• W3185280489 hasConceptScore W3185280489C126322002 @default.
• W3185280489 hasConceptScore W3185280489C126894567 @default.
• W3185280489 hasConceptScore W3185280489C143998085 @default.
• W3185280489 hasConceptScore W3185280489C168563851 @default.
• W3185280489 hasConceptScore W3185280489C17744445 @default.
• W3185280489 hasConceptScore W3185280489C187960798 @default.
• W3185280489 hasConceptScore W3185280489C189708586 @default.
• W3185280489 hasConceptScore W3185280489C197934379 @default.
• W3185280489 hasConceptScore W3185280489C199539241 @default.
• W3185280489 hasConceptScore W3185280489C2779473830 @default.
• W3185280489 hasConceptScore W3185280489C2780192828 @default.
• W3185280489 hasConceptScore W3185280489C29456083 @default.
• W3185280489 hasConceptScore W3185280489C44249647 @default.
• W3185280489 hasConceptScore W3185280489C71924100 @default.
• W3185280489 hasConceptScore W3185280489C82789193 @default.
• W3185280489 hasConceptScore W3185280489C95190672 @default.
• W3185280489 hasIssue "2" @default.
• W3185280489 hasLocation W31852804891 @default.
• W3185280489 hasLocation W31852804892 @default.
• W3185280489 hasOpenAccess W3185280489 @default.

• next